Clinical Trial Update: A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of SGT-53 in children with refractory or recurrent solid tumors has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• SGT-53

Snippet

Sponsor: SynerGene Therapeutics, Inc. | Conditions: Neoplasm | Phase 1 | Status: SUSPENDED